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Abstract Mast cells contain granules packed with a
mixture of proteins that are released on degranulation.
The proteoglycan serglycin carries an array of glycos-
aminoglycan (GAG) side chains, sometimes heparin,
sometimes chondroitin or dermatan sulphate. Tight
packing of granule proteins is dependent on the pres-
ence of serglycin carrying these GAGs. The GAGs of
mast cells were most intensively studied in the 1970s
and 1980s, and though something is known about the
fine structure of chondroitin sulphate and dermatan sul-
phate in mast cells, little is understood about the com-
position of the heparin/heparan sulphate chains. Recent
emphasis on the analysis of mast cell heparin from dif-
ferent species and tissues, arising from the use of this
GAG in medicine, lead to the question of whether var-
iations within heparin structures between mast cell pop-
ulations are as significant as variations in the mix of
chondroitins and heparins.
Keywords Mast cell . Heparin . Chondroitin . Dermatan .
Glycosaminoglycan . Serglycin
Introduction
Mast cells originate from bone-marrow derived leukocytes,
and are distributed to tissue locations outside the vasculature
before maturing under the influence of stem cell factor (SCF)
and IL-3 to phenotypes characteristic of each tissue [1–3]. The
most striking feature of mast cells is their large secretory gran-
ules (Fig. 1), that contain a formidable arsenal of proteases,
small molecule biogenic amines, and cytokines ready for re-
lease when mast cells degranulate as a response to external
stimuli, in a rapid pro-inflammatory reaction to the possible
presence of an invading organism.
The granule contents are closely packed, with the help of
the proteoglycan serglycin, and its GAG sidechains [4]. The
intracellular GAGs stored in granules of mast cells (and a few
other cell types, such as basophils) are an interesting set of
compounds. GAGs are largely thought of as being displayed
to the extracellular space, on the surfaces of cells and in the
extracellular matrix. In this context they may play structural
roles, or may interact with morphogens, cytokines and other
small protein messengers, guiding their location in tissue or
acting as cell surface receptor components [5]. The struc-
tures and roles of mast cell granule GAGs are not at pres-
ent a well-pursued research topic, with the exception of
studies concerning the HS variant known as heparin. This
polysaccharide is isolated from intestinal mucosa of pigs,
cattle and sometimes sheep in kilogram quantities, to be
used as an antithrombotic agent in medicine [6]. Given its
location in mast cell granules, it is not clear what the
native function might be of the potent anticoagulant ac-
tivity of heparin, mediated by its high-affinity, specific
interaction with the plasma serine protease inhibitor
(serpin) antithrombin [7]. We believe that the time is ripe
for a revival of interest in the structures and functions of
mast cell granule GAGs.
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Serglycin, the mast cell granule proteoglycan
The mast cell granule proteoglycan, serglycin, has a small pro-
tein core; the human sequence is 158 amino acids long, includ-
ing an N-terminal signal peptide. It contains a central domain in
which serine and glycine alternate; the human sequence has 8
serines in this sequence, and the mouse has ten, whereas the rat
sequence is much longer, containing 24 serines [8]. Serine res-
idues in this region may bear galactosaminoglycan sidechains,
either chondroitin-4-sulphate (CS-A) or dermatan sulphate
(DS; CS-B); or glucosaminoglycan chains of the heparan
sulphate/heparin family. It has not been established whether
the same protein core carries both types of GAG chain or
whether they are segregated in different proteoglycan
molecules.
In 1971, a macromolecular form of heparin was prepared
from rat skin, with a molecular weight of more than 100 kDa
[9], and later the complete rat peritoneal mast cell heparin
proteoglycan, serglycin, was found to have a molecular
weight of about 750 kDa, with heparin chains of about
75 kDa attached to a protease resistant core [10]. The term
‘serglycin’ came into use later in that decade [11, 12].
Serglycin varies in its GAG substitution between different cell
types and between sub-populations of mast cells in different
environments [13, 14], as discussed below. The GAG substit-
uents of serglycin make up most of its molecular weight, and
variability in the number and length of polysaccharide
sidechains, together with the difficulty of isolation of whole
serglycin, probably explains why the estimated molecular
weight of serglycin varies between 60 KDa and 750 kDa
[4]. Estimates at the higher end of this range lead to the con-
clusion that most of the serines in the alternating SG sequence
are GAG substi tuted, implying a tightly packed,
conformationally restricted environment for the GAG linkage
sequence and nearby GAG repeating sequence (Figs 2 and 3).
Heparin and chondroitin sulphate in mast cell
granules: biosynthesis of mast cell GAGs
The GAG biosynthetic machinery of mast cells is similar
to that of any other cell. The linkage sequence, −3Galβ1–
3-Galβ1–4-Xyl-O-Ser, is common to both the galactos-
amine and glucosamine containing types of GAG. The
next monosaccharide is glucuronic acid (GlcA), added
by the enzyme GlcAT-1, and after that either GalNAcT-1
or GlcNAcT-1 commits the site to either chondroitin or
heparin/HS substitution, respectively [5]. GAGs are built
up from this common linker sequence of sugars by a se-
ries of enzymes that elongate the linear polysaccharide
chain, add sulphate substituents, and epimerise some
GlcA residues to α-L-iduronic acid (IdoA); the processes
Fig. 1 a, b Transmission electron
micrographs showing an intact rat
peritoneal MC (a) and a MC
undergoing anaphylactic
degranulation (b). The block
arrows indicate regions where
multiple granules have fused; the
arrow depicts an exocytosed
granule remnant. c, d Scanning
electron micrographs showing an
intact (c) and degranulated (d) rat
peritoneal MC. Note the
extensive membrane alterations in
d. Arrows in d depict exocytosed
granule remnants. Images are
courtesy of Prof. Giuliano
Zabucchi, Prof. Maria Rosa
Soranzo, and Dr. Francesca Vita
(Electron Microscopy Section of
Centro Coordinamento e
Sviluppo Progetti e
Apparecchiature (CSPA),
University of Trieste). Figure and
caption reproduced with
permission from [39]
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for biosynthesis of the chondroitins [15] and for heparan
sulphate [16] (Figs 2a and b) have been described. There
is, however, a difference between the biosynthetic path-
ways for HS in other cell types and mast cell heparin, in
the first of the post-polymerization enzymes to modify the
polysaccharide chain; N-deactylase, N-sulphotransferase
(NDST). The isoform NDST-1 introduces short sequences
of N-sulphated residues into the HS structure; the isoform
NDST-2 introduces much longer, almost continuous N-
sulphated domains into heparin [17].
Mast cell GAGs are highly sulphated, and there are several
sulphate-related structural motifs associated with the particu-
lar functions of mast cell heparin and chondroitin sulphates.
Best understood, perhaps, is the pentasaccharide structure in
heparin that has high affinity for antithrombin (Fig. 2c).
Though this is not a common sequence, it is more abundant
Fig. 2 GAG structures found in
mast cells. a The main repeating
unit of heparan sulphate, [ −4)-β-
D-GlcA-(1→ 4)-α-D-GlcNAc-
(1- ] (GlcA-GlcNAc). This
structure forms the precursor
polysaccharide, which is
transformed by a series of
enzymes into b the main
repeating unit of heparin [−4)-α-
L-IdoA(2SO3
−)-(1→ 4)-α-D-
GlcNSO3
−(6SO3
−)-(1-] (IdoA2S-
GlcNS6S). c the pentasaccharide
with high affinity for
antithrombin, as found in porcine
mucosal heparin; essential
substituents are marked with an
asterisk. The enzyme 3-O-
sulfotransferase (3-OST) isoform
1 adds the unusual 3-O-sulphate
substituent (indicated with a
double asterisk) to the central N-,
6-disulphated glucosamine in the
GlNR6S-GlcA-GlcNS,6S–
IdoA2S-GlcNS,6S sequence
Fig. 3 The conversion of the
chondroitin backbone to CS-A,
CS-B, CS-C, CS-D, CS-E and
CS-diB by the enzymes
chondroitin-4-sulfotranferase
(C4ST), GlcA 5-epimerase (DS-
epi), dermatan 4-O-
sulfotransferase (D4ST),
chondroitin 6-sulfotransferase
(CS6ST) uronosyl 2-O-
sulfotransferase (UST) GalNAc
4-O- sulphate 6-O-
sulfotransferase (GalNAc4S-
6ST). Reproduced with
permission from [15]
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in heparin than in most heparan sulphates [18]. The central
glucosamine in the pentasaccharide bears three sulphates; it is
3-O-sulphated, besides having regular 2-N-sulphation and 6-
O-sulphation. The 3-O-sulfotransferase (3-OST) that intro-
duces this substitution has several isoforms, and it is 3-OST-
1 that is effective in the mast cell [19]. The glucosamine sub-
strate residue is preceded (at the nonreducing side) by GlcA
rather than IdoA.
The presence of disulphated disaccharide units in chondroitin
sulphate frommast cells has long been recognised. Two of these
structural units are commonly encountered, the 4,6 sulphated
CS-E motif and the 2,4 sulphated CS di-B motif (Fig. 3). The
enzyme responsible for the CS-E motif,N-acetylgalactosamine-
4-sulphate-6-O-sulphotransferase, was shown to be expressed in
mouse mast cells, and to act on internal as well as non-reducing
terminal GalNAc4S [20]. The CS di-B disaccharide is achieved
by sulphation of IdoA in the 4-O-sulphated dermatan repeat
disaccharide to IdoA2S, by the uronosyl-2-O-sulphatase
(UST) enzyme, also responsible for converting 6-sulphated
CS-C to CS-D (Fig. 3) [21]. The occurrence of several di-B
disaccharides in succession gives rise to the high-affinity se-
quence for heparin cofactor II, a thrombin inhibiting serpin that
can be activated by either heparin or DS [22].
GAGs inmast cell sub-populations and in other leukocytes
Research in rodent species led to the definition of two mast
cell subtypes, the connective tissue mast cells (CTMCs) and
mucosal mast cells (MMCs); CTMCs are constitutive and T
cell independent whereas MMCs are induced and T-cell de-
pendent [23]. The maturation process of the mast cells also
results in differences in granule contents, for example different
profiles of granule proteases. They are also histochemically
different; CTMC granules can be stained with safranin, where-
as MMCs cannot, though both types of cell can be stained
with alcian blue. This has been attributed to systematic differ-
ences in GAG content of the two cell types. The fluorescent
dye berberine has also been used to stain CTMC granules, but
does not stain MMCs from the intestine [24]. Berberine and
safranin staining were used to demonstrate that cultured mast
cells could take on the characteristics of CTMCs or MMCs
when transplanted into mast cell deficient mice, depending on
the tissue to which they were introduced [25], and in fact both
CTMCs and MMCs originate from the same precursor bone
marrow mast cells [23].
The statement sometimes encountered, that heparin is only
found in connective tissue mast cells, and not in mucosal mast
cells, is a generalisation based on studies on rodent mast cells in
the 1970s and 1980s. Certainly, heparin has been identified in
CTMCs from rat peritoneum [26] and found to be present in
minor amounts, or completely absent, in MMCs from the in-
testines of nematode-infected rats [27–29]. In humans, both
connective tissue mast cells and mucosal mast cells were found
to contain GAGs with high affinity for antithrombin, using an
antithrombin-gold stain [30]. The same system was able to
distinguish between rat CTMCs and MMCs. It may be that
humans do not have the exact equivalent of rodent MMCs.
The GAGs of rat leukaemic basophils have been identified
as chondroitins 4- and 6-O- sulphate, dermatan sulphate, and
heparin [31]. Using disaccharide analysis by HPLC against
standard compounds, GAGs from platelets and mixed
granulocytes were found to be of the CSA/DS type, with a
small amount of CS-E and CS-diB.
Recently, detailed analysis of leukocyte GAGs has identi-
fied 4-O-sulphated CSA (not DS) as the major GAG compo-
nent in several cell types, with a small proportion of a highly
sulphated heparin-like HS (the study did not separate granule
from cell surface GAGs, but assumes that the proportion of
cell surface GAGs is small) [32].
Fine structure of mast cell GAGs
The most common method for analysis of mast cell GAGs is
enzymatic depolymerisation followed by chromatographic or
electrophoretic separation and quantitation of the resulting
oligosaccharides. The availability of chondroitinase enzymes,
and the ability to separate the oligosaccharide products of
chondroitinase digestion, meant that more detailed analysis
of the chondroitins found in mast cells was possible in early
studies than was the case for heparin/HS-like GAGs. The
chondroitin sulphates of rat MMCs have been described as a
mixture of CSA and CSE [27], or as a mixture of CSA and
CSdi-B [28] or as a mixture of monosulphated CS, with both
CSE and CSdiB [29]. In all cases, the disulphated CS ele-
ments, such as CS-diB and CS-E, are found together with
monosulphated, particularly CS-A disaccharides.
It has been pointed out that the use of chondroitinase di-
gestion leaves the nature of the original uronic acid in each
disaccharide uncertain, as IdoA andGlcA give rise to the same
unsaturated uronic acid at the non-reducing end of cleaved
oligosaccharides; so, for example, the 2,4-O-disulphated di-
saccharide (CS-diB), though it is generally assumed to come
from dermatan sulphate, might conceivably originate from a
chondroitin polysaccharide containing a motif in which the
GlcA is 2-O-sulphated [29]. Certainly, the ‘CS-A’ disaccha-
rides could as easily be derived from dermatan sulphate as
from CS-A itself, and indeed this has been shown to be the
case for rat peritoneal mast cells, in which the 4-O-sulphated
galactosaminoglycan is susceptible to chondroitinase ABC
but not to chondroitinase AC, which does not cleave dermatan
(CS-B) [33]. This has recently been confirmed by direct NMR
spectroscopic analysis of rat peritoneal mast cell GAGs [35].
More recently, it has become possible to perform disaccha-
ride analysis on heparin/HS as well as on CS, as for example
in a study of bone marrow derived mast cells of Ctr2−/− mice
354 Glycoconj J (2017) 34:351–361
(Ctr2 is a protein that regulates mobilisation of endosomal Cu
pools). The Ctr2−/−mast cells contained more heparin and less
CS than wild type controls [34], with a considerable increase
in 6-O-sulphation of glucosamine due to increased expression
of the HS6ST-1 sulfotransferase enzyme. A particularly inter-
esting study of GAGs derived from leukocytes of individual
human subjects was able to compare disaccharide composi-
tion and CS chain lengths for polymorphonuclear cells
(PMNs), peripheral blood mononuclear cells (PBMCs), T-
and B-cells, natural killer (Nk) cells and monocytes [32], iden-
tifying a remarkable consistency in the disaccharide composi-
tion of leukocyte HS/heparin between subjects.
As the sequence of serglycin does not vary between
mast cell subtypes in a single species, differences in their
proportions of heparin/HS and chondroitin GAG substitu-
ents cannot be dependent on the peptide sequence near the
linkage site. It may be that the mechanism through which
the local mast cell environment can determine the GAG
type on its serglycin is related to the GalNAc-T1/GlcNAc-
T1 stage of GAG chain initiation; in addition other influ-
ences such as availability of nucleotide monosaccharide
donors and the sulphate donor 3′-phosphoadenosine-5′-
phosphosulphate (PAPS) may play a part.
Interactions between GAGs and other granule
contents
The many small molecules and peptides found in mast cell
granules have recently been listed [2]. They include small
molecules such as biogenic amines, and a set of mast cell
specific proteases as well as many other proteins. These pro-
teases differ between species, in particular between human
and rodent mast cells.
The storage of histamine and serotonin in mast cell gran-
ules is dependent on the presence of serglycin [36]. Histamine
can bind to heparin at a density of one molecule of histamine
to one disaccharide unit in a highly ordered fashion [37]. The
relatively low pH ofmast cell granules increases the affinity of
this electrostatic interaction, and the increase in pH on release
into surrounding tissue reduces affinity.
GAGs and mast cell proteases
The proteases specific to mast cell granules are chymases,
tryptases and carboxypeptidase A3; in human mast cells there
is one chymase and a limited repertoire of tryptases compared
with the numerous mouse enzymes [2]. In addition to these,
several other proteases occur in mast cell granules but are not
specific to them; examples are cathepsin G, granzyme B [2],
and cathepsin E, which cleaves the carboxypeptidase A pre-
cursor to give the active enzyme [38]. Proteases in mast cell
granules are stored in their active forms [39]. The functions of
mast cell proteases in inflammation and tissue repair [40], and
those of protease-proteoglycan complexes in innate immunity
[41] have been reviewed. These proteases are well recognised
as pharmacological targets [42].
Mast cell protease storage is dependent on serglycin, and is
moreover dependent on the presence of heparin and/or chon-
droitin, as demonstrated in NDST2−/− mice that do not make
the fully sulphated heparin structure [43, 44] and GalNAc4S-
6OST−/− mice that cannot generate the CS-E structure [45].
No evidence has been reported that fully anticoagulant hepa-
rin, containing the 3-OST product sequence, is necessary for
protease storage.Mouse CTMCs deficient in a combination of
proteases have much reduced heparin, but unaltered chondroi-
tin content [46]. Protease deficient, serglycin deficient, and
heparin deficient mast cells all display altered granule mor-
phology [43, 44, 46, 47].
In the mast cell granule, proteases and heparin are in intimate
contact, so extensive heparin binding sites containing basic res-
idues are expected on the surfaces of the proteases. For
tryptases, dependent on heparin for activity and stabilisation of
the tetrameric form [48], a plausible cross-linking geometry has
been described for human β-II tryptase [49] (Fig. 4a) and a
potentially heparin-binding linear area of basic character has
been identified across two monomeric units in the tetramer of
human α1-tryptase (Fig. 4b) [50]. Besides the active tetrameric
form, stabilised by heparin, tryptases such as human β-tryptase
and mouse mMCP-6 can also form active monomers in the
presence of heparin, even if the heparin chain is too small to
bridge two protein monomers (though heparin of such a low
molecular weight is not likely to be found in vivo) [51, 52].
The minimum length of heparin for complex formation with
tryptase tetramer is 20 monosaccharides [53]. The sub-
strate selectivities for monomeric and tetrameric tryptases
are different, and the monomeric form is susceptible to
inhibition by protein inhibitors such as BPTI [51]; in the
tetrameric form the active sites of the four monomers face
each other round a restricted space in the centre of the
complex, restricting access to inhibitors that are proteins.
As the tetramer is most stable at low pH and in the presence
of heparin, it has been proposed that tryptases are stored in the
tetrameric form [54], and the presence of two separate, linear
heparin binding sites on each tetramer, requiring long heparin
chains, is compatible with the formation of closely packed
complexes with heparin chains attached to a serglycin core.
Depolymerisation of heparin, degranulation, and rise in pH
could dissociate the tetramers to give heparin-activated, effec-
tive monomers, or inactive monomers as the heparin dissoci-
ates over time.
It is interesting to note that antithrombin is capable of
inhibiting the monomeric active form of tryptase [55]; so heparin
can either activate the serine protease or potentiate its inhibition if
all three are found together. Tetrameric, heparin-associated
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human tryptase can prevent coagulation and formation of fibrin
deposits in inflamed tissue by cleaving fibrinogen [56].
For human chymase and granzyme B, typical heparin/HS
binding sites can be identified. Chymase is active as a
monomer, and does not require heparin for its activity. It has
two separate well-defined patches of basic residues that may
constitute heparin-binding sites, on opposite faces of the pro-
tein surface (Fig. 4c). There is only one human chymase (ro-
dents have several), and its presence or absence determines the
classification of human mast cells into MCTC mast cells, pos-
itive for both tryptase and chymase, and MCT cells, positive
for tryptase only [2]. These two cell types are considered ap-
proximately equivalent to rodent CTMCs and MMCs, respec-
tively. It is likely that this classification is an oversimplifica-
tion of the true situation, at least in tissues like the lung [57].
Granzyme B has a particularly clear basic patch, shown on the
protein surface in Fig. 4d. All of these potential heparin bind-
ing sites on the proteases have different sizes and shapes; they
may have different affinities for heparin, different abilities to
bind to more than one heparin chain in the granule, different
requirements in terms of heparin chain length, and even pos-
sibly different preferences for fine structure within heparin. It
is also possible, of course, that preferences for CS/DS struc-
tures vs heparin structures differ between proteases.
Heparanase and the depolymerisation of serglycin
In 1971, Ogren and Lindahl [58] described enzymatic
depolymerisation of mouse macromolecular heparin to yield
heparin chains of about the range of molecular weights found
in commercial samples.
The average molecular weight of heparin sodium USP is
somewhere between 15 kDa and 19 kDa; not more than 20%
material by weight is over 24 kDa, and about 10% is less than
8 kDa [59]. As far as it is possible to tell, the molecular weight
distributions of commercial porcine mucosal heparin have
fallen roughly within that range for decades [60]; the USP’s
formal limits have only recently been introduced [59, 61].
Differences in manufacturing processes have only a minor
influence over molecular weight [59], so for the most part,
commercial heparin retains the molecular weight it had on
extraction from hog mucosa.
The endoglucuronidase known as heparanase has been
shown to depolymerise heparin in the mast cell granule [62]
and is thought to play an important part in maintaining ho-
meostasis in granules; overexpression of heparanase reduces
heparin chain size and protease storage capacity, whereas lack
of heparanase leads to increase in heparin chain length and
protease content [63]. The preferred substrate sequence for
heparanase is at the junction between non epimerized, less
sulphated sequences and the non-reducing side of highly
sulphated sequences, such as at the GlcA-GlcNS6S linkage
[64]. Heparin, largely made up of IdoA2S-GlcNS,6S disac-
charides, is therefore cleaved not into short oligosaccharides,
but into longer lengths, giving rise to the molecular weight
profile of commercially produced heparin. Mast cells vary in
Fig. 4 Heparin interactions with proteases a A β-tryptase tetramer
crystal structure (1A0L.pdb), coloured by charge where blue is positive
and red negative. This view clearly shows the restricted central active site.
Clusters of basic residues, coloured blue, might accommodate a heparin
chain binding to two monomers and so stabilising the active tetramer.
Diagram made in Discovery Studio Visualiser, Accelrys Software Inc. b
An α-tryptase tetramer crystal structure (1LTO.pdb), turned over by 90°
to show the equivalent of the top face as compared with A). This view
shows an almost continuous line of basic amino acid residues aligning
with a long heparinmolecule, shown in ball and stick format. Reproduced
from [50] with permission. c A chymase monomer crystal structure
(4KP0.pdb), showing clusters of basic amino acid residues (blue) on
opposite sides of the charge-coloured surface, with a cluster of acidic
residues (red) between them. The orientation of these two basic patches
on the surface of chymase might allow this enzyme to pack between
heparin chains of serglycin. The active site groove is on the left face of
this diagram. Diagram made in Discovery Studio Visualiser, Accelrys
Software Inc. d A granzyme B monomer crystal structure (1IAU.pdb)
showing a substantial cluster of basic residues (blue) at the top of the
charge-coloured surface. The active site is on the left face of the diagram.
Diagram made in Discovery Studio Visualiser, Accelrys Software Inc
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their heparanase content [63]; rat skin mast cells presumably
contain little heparanase, so that complete serglycin, or mac-
romolecular heparin, can be prepared from them in spite of the
fact that it provides a substrate for heparanase [62, 65]. The
partial depolymerisation of serglycin heparin by heparanase
has been found to aid the release of proteases on degranulation
[66]. No equivalent enzyme for the depolymerisation of mast
cell granule CS/DS has been identified, as far as we know.
Mast cell GAGs after degranulation
On mast cell degranulation, a substantial list of pre-formed
mediators are released into the extracellular space, among
them the biogenic amines histamine and serotonin, the mast
cell specific proteases described above, other non-mast cell
specific proteases, cytokines and of course serglycin proteo-
glycan and heparanase-cleaved heparin polysaccharide [39].
Presumably also the chondroitin/dermatan sidechains of
serglycin are released. The effects of high concentrations of
these mediators in a limited three-dimensional space, and the
differential time courses of diffusion and breakdown of
protease-serglycin complexes that eventually disperse these
agents, is not yet completely understood. It has been found
that mouse mast cell protease-7 (mMCP-7) disperses away
from the site of degranulation into the blood more quickly
than mMCP-6: this is consistent with the histidine-based hep-
arin binding site of mMCP-7, which loses affinity at neutral
pH, as compared with the lysine and arginine based heparin
binding site of mMCP-6, which does not [67]. Heparin can
have a stabilising and activating influence on protease activity,
and can also potentiate serine protease inhibitors, so its role
may change according to the relative concentrations of pro-
teins and GAGs over time.
Heparin has been shown to be released extracellularly after
IgE mediated degranulation of mast cells from human lung
tissue [68] and has been proposed to act as a homeostatic
Bbraking^ mechanism limiting the extent of inflammation in
an analogous way to homeostatic controlling mechanisms
limiting the actions of neurotransmitters and hormones in the
nervous and endocrine systems [69]. However, there are only
limited data on the biological activity of endogenously re-
leased GAGs. Thus, heparin derived from rat mast cells has
been shown to have anti-proliferative activity for vascular
smooth muscle cells [70] and more recently we have demon-
strated that endogenous heparin obtained from rat peritoneal
mast cells inhibits the adhesion of neutrophils to vascular en-
dothelial cells in vivo and the recruitment of inflammatory
cells into the peritoneum [35]. Nonetheless multiple studies
have now shown that heparin can bind to many proteins in-
volved in different stages of the inflammatory cascade in-
volved in the recruitment of inflammatory cells from blood
into extravascular tissues, including adhesion to vascular
endothelium, rolling on endothelial cells and the subsequent
diapedesis across the endothelium [71]. This is as a conse-
quence of many of the adhesion molecules involved in this
cascade having heparin binding domains in their structure.
Once bound, heparin inhibits the adhesion molecule
recognising its counter ligand and thus prevents the physio-
logical function that would normally have arisen if the adhe-
sion molecules were allowed to bind. Furthermore, heparin
can bind to certain chemokines that can trigger the recruitment
of leukocytes into tissues [72], as well as binding to a number
of cationic pro-inflammatory molecules released from activat-
ed leukocytes such as neutrophil elastase and eosinophil de-
rived major basic protein [7]. By binding these cationic mol-
ecules heparin effectively neutralises their ability to cause tis-
sue damage. Not surprisingly therefore exogenously adminis-
tered heparin has been shown to have a wide variety of anti-
inflammatory actions in vivo, both experimentally and clini-
cally (reviewed in [7]).
Heparin from different tissues and species
Currently, heparin for medicinal use in the USA and Europe is
prepared from porcine mucosa, and in other parts of the world
bovine mucosal heparin is in use. Heparins from these sources
have been compared by spectroscopic, molecular weight de-
termination and degradative analyses, and found to be differ-
ent in their disaccharide compositions [6, 73–75]. In the past,
bovine lung heparin was available, but fell out of use partly for
cost reasons and partly due to caution in the use of bovine-
derived products in the wake of the discovery of transmissible
spongiform encephalopathies (TSEs) in cattle [76].
Some exploration of other species and tissues has taken
place, for example the preparation of a raw heparin from
dromedary intestine [77]; or a less promising alternative of
heparin from an avian source, turkey intestine, that yielded
only relatively low-sulphated, less active HS [78].
Heparin has been prepared for research purposes from
many animal species, ranging from a classic study of tissue
distribution of heparin in eight mammalian species including
man to reports of heparin-like GAGs in marine invertebrates
[79]. Molluscs, such as the mussel Anodonta anodonta, con-
tain heparin similar to that from mammalian sources [80], and
several species of clam contain highly anticoagulant heparin
[81, 82]. A detailed analysis of such a heparin from the clam
Tapes phylippinarum revealed that the pentasaccharide with
high affinity for antithrombin has the same structure as that
from bovine and porcine mucosal heparin [83] (Fig. 2c). Clam
heparin occurs in mast-like cells near epithelial surfaces [84,
85]. Ascidian test cells containing heparin-like structures in
granules [86, 87] may well be related to mast cells [88]; like
mast cells, test cells are likely to be involved in defence
against infection [89]. Heparin has also been found in
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haemocytes of the ascidian Styela plicata [90], and this cell
type may also be related to mammalian mast cells [1]. The
idea that heparin has a common role in both vertebrates and
invertebrates has been explored [91].
In most of these studies, heparin was prepared by fraction-
ation of heparin from GAG mixtures obtained from whole
tissues, rather than from isolated mast cells. It is necessary to
assume, in these cases, that HS-type glucosaminoglycans with
a high degree of sulphation and substantial anticoagulant ac-
tivity represent mast cell derived heparin, rather than heparan
sulphate from other cell types. This assumption is not unrea-
sonable for heparin but cannot at all be made for chondroitin
sulphates; we have almost no information on the variability of
mast cell chondroitins between species.
Particularly interesting is human heparin, prepared from a
large hemangioma, that has been compared in detail with por-
cine mucosal heparin; heparins from the two sources are sim-
ilar, with human heparin having, if anything, higher anticoag-
ulant potency [92]. Heparin from human placenta has also
been prepared [93].
It is also interesting to note the variability in heparin se-
quence and structure between different tissues in the same
species. A comparative study of 12 tissues in eight species
yielded heparins with a variety of different molecular weights
and anticoagulant activities, all of which gave trisulphated
disaccharide on digestion with heparinase I [94].
Commercial heparin derived from bovine lung and from bo-
vine intestinal mucosa are clearly and consistently different in
structure [75]. Mast cells in different environments do not
simply choose between heparin and chondroitin GAGs, but
mobilise the sets of biosynthetic enzymes that determine the
fine structure of heparin and chondroitin in different ways.
Conclusions
Though the distinction between CTMCs and MMCs in ro-
dents has justification, it is probably not safe to assume that
this simple dichotomy can be extended to all tissues and all
species. Even if it is true that less heparin is present in MMCs
than in CTMCs, enough heparin can be obtained from the
intestinal mucosae of large food animals to support a substan-
tial pharmaceutical industry. Mast cells have the apparatus to
assemble any serglycin the local tissue environment requires.
Different heparin structures determined for different tissues
within the same species indicate that mast cell populations
differ not only in the proportions of different GAGs, but in
the fine structure of those GAGs as well. However, there are
strong similarities in heparin structures across the entire ani-
mal kingdom, including the presence of the pentasaccharide
sequence with high affinity for the serpin antithrombin.
Serpins are present in all multicellular eukaryotes [95], so
are at least as ubiquitous as glycosaminoglycans, and they
are not all, like antithrombin, concerned with blood coagula-
tion but inhibit proteolytic cascades in a number of contexts
[96]. The functional significance of mast cell GAG fine struc-
ture may be concerned with the role of heparin after degranu-
lation, and may be involved in inflammatory or anti-
pathogenic roles of mast cells [79, 93].
In summary, there remain many gaps in our understanding
of the structure and function of mast cell GAGs.We know that
their overall anionic nature is crucial to correct packing of
granule proteases, but we have no functional explanation for
the differences in GAG fine structure that exist between spe-
cies and tissues. There is a great deal of scope for future work
in this field.
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